Tampere, Finland
Tampere, Finland
SEARCH FILTERS
Time filter
Source Type

News Article | May 3, 2017
Site: globenewswire.com

TIEDOTE, 3. TOUKOKUUTA 2017 OSAKKEET FIT BIOTECH OY: VAIHDETTAVALLA PÄÄOMALAINALLA MERKITYT OSAKKEET Yhteensä 1 089 324 osaketta otetaan kaupankäynnin kohteeksi yhdessä vanhojen K-osakkeiden kanssa 4. toukokuuta 2017. FIT Biotech Oy:n K-osakkeen perustiedot: Kaupankäyntitunnus: FITBIO ISIN-koodi: FI4000148606 id: 109536 Osakemäärä: 59 014 123 Nasdaq Helsinki Oy, Issuer Surveillance, survo@nasdaq.com, +358 9 6166 7260


News Article | May 3, 2017
Site: globenewswire.com

TIEDOTE, 3. TOUKOKUUTA 2017 OSAKKEET FIT BIOTECH OY: VAIHDETTAVALLA PÄÄOMALAINALLA MERKITYT OSAKKEET Yhteensä 1 089 324 osaketta otetaan kaupankäynnin kohteeksi yhdessä vanhojen K-osakkeiden kanssa 4. toukokuuta 2017. FIT Biotech Oy:n K-osakkeen perustiedot: Kaupankäyntitunnus: FITBIO ISIN-koodi: FI4000148606 id: 109536 Osakemäärä: 59 014 123 Nasdaq Helsinki Oy, Issuer Surveillance, survo@nasdaq.com, +358 9 6166 7260


News Article | May 3, 2017
Site: globenewswire.com

TIEDOTE, 3. TOUKOKUUTA 2017 OSAKKEET FIT BIOTECH OY: VAIHDETTAVALLA PÄÄOMALAINALLA MERKITYT OSAKKEET Yhteensä 1 089 324 osaketta otetaan kaupankäynnin kohteeksi yhdessä vanhojen K-osakkeiden kanssa 4. toukokuuta 2017. FIT Biotech Oy:n K-osakkeen perustiedot: Kaupankäyntitunnus: FITBIO ISIN-koodi: FI4000148606 id: 109536 Osakemäärä: 59 014 123 Nasdaq Helsinki Oy, Issuer Surveillance, survo@nasdaq.com, +358 9 6166 7260


News Article | May 15, 2017
Site: globenewswire.com

TIEDOTE, 15. TOUKOKUUTA 2017 OSAKKEET FIT BIOTECH OY: VAIHDETTAVALLA PÄÄOMALAINALLA MERKITYT OSAKKEET Yhteensä 1 043 432 osaketta otetaan kaupankäynnin kohteeksi yhdessä vanhojen K-osakkeiden kanssa 16. toukokuuta 2017. FIT Biotech Oy:n K-osakkeen perustiedot: Kaupankäyntitunnus: FITBIO ISIN-koodi: FI4000148606 id: 109536 Osakemäärä: 60 057 555 Nasdaq Helsinki Oy, Issuer Surveillance, survo@nasdaq.com, +358 9 6166 7260


News Article | May 15, 2017
Site: globenewswire.com

TIEDOTE, 15. TOUKOKUUTA 2017 OSAKKEET FIT BIOTECH OY: VAIHDETTAVALLA PÄÄOMALAINALLA MERKITYT OSAKKEET Yhteensä 1 043 432 osaketta otetaan kaupankäynnin kohteeksi yhdessä vanhojen K-osakkeiden kanssa 16. toukokuuta 2017. FIT Biotech Oy:n K-osakkeen perustiedot: Kaupankäyntitunnus: FITBIO ISIN-koodi: FI4000148606 id: 109536 Osakemäärä: 60 057 555 Nasdaq Helsinki Oy, Issuer Surveillance, survo@nasdaq.com, +358 9 6166 7260


News Article | May 15, 2017
Site: globenewswire.com

TIEDOTE, 15. TOUKOKUUTA 2017 OSAKKEET FIT BIOTECH OY: VAIHDETTAVALLA PÄÄOMALAINALLA MERKITYT OSAKKEET Yhteensä 1 043 432 osaketta otetaan kaupankäynnin kohteeksi yhdessä vanhojen K-osakkeiden kanssa 16. toukokuuta 2017. FIT Biotech Oy:n K-osakkeen perustiedot: Kaupankäyntitunnus: FITBIO ISIN-koodi: FI4000148606 id: 109536 Osakemäärä: 60 057 555 Nasdaq Helsinki Oy, Issuer Surveillance, survo@nasdaq.com, +358 9 6166 7260


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-09-2015 | Award Amount: 28.14M | Year: 2016

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2009-2.3.2-4 | Award Amount: 15.44M | Year: 2010

Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cellular immune responses specific to HIV antigens. Composed by 13 partners from 5 European countries and 2 International Cooperation countries, the CUTHIVAC consortium gathers knowledges and cutting-edge technologies in vaccinology and HIV diseases to raise the challenge of developing a new HIV strategy. The CUTHIVAC approach is based on innovative transcutaneous and/or mucosal needle-free vaccination methods in a perspective that new vaccine candidates will redirect immune response toward cytotoxic CD8 and mucosal humoral responses. The trust of the project derives from the proof-of-concept that combination of routes of immunization and delivery systems will shape the immune responses towards its protective arms against HIV. Clinical trials will be implemented with last cutting-edge generation of HIV DNA-GTU candidate applied by transcutaneous, intradermal routes and/or mucosal administration of HIV-envelop protein-based vaccine. Large efforts will be positioned on the new genetic design of HIV antigens and delivery systems for developed and developing countries. These new vaccines will be tested in innovative preclinical approaches with a special highlight on routes of vaccination that will be translated into 2nd round of clinical trials in a perspective that could help to prevent and eradicate HIV. Through its integrative and multidisciplinary approach, CUTHIVAC will therefore provide the basis for a novel approach in vaccination with a view to wide its application to other infectious diseases such as malaria and tuberculosis.


Patent
FIT Biotech | Date: 2014-01-13

A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.


The present invention relates to a novel selection system, which is based on the use of an araD gene, a mutated form of an araD gene, a complementary sequence thereof, or a catalytically active fragment thereof as a selection marker and to the use of a bacterial strain deficient of the araD gene. The present invention further relates to novel vectors containing an araD gene, a mutated form of an araD gene, a complementary sequence thereof, or a catalytically active fragment thereof and to novel bacterial strains deficient of the araD gene. The present invention additionally relates to a method of selecting the cells transformed with a plasmid, which contains the gene of interest.

Loading FIT Biotech collaborators
Loading FIT Biotech collaborators